Cure TV

The understanding of genetic mutations, like tumors that are microsatellite instability-high (MSI-H), and the therapies that go along with them is transforming the world of colorectal cancer, according to John Marshall, M.D.

William J. Gradishar, M.D., discusses the potential surgical implications for a woman with breast cancer who tests positive for a BRCA mutation, and why it is important to be aware of this genetic information.

The time has finally come when researchers have found a way to harness the immune system and use it to fight blood cancers.

Immunotherapy use continues to expand in the cancer treatment space. So, it is important that patients and caregivers understand its potential side effects.

The definition of smoldering myeloma was reworked in recent years.

Colorectal cancer expert John Marshall, M.D., shares his feelings about the month of March, which is Colorectal Cancer Awareness month.

Ruben Mesa, M.D., director of the UT Health San Antonio Cancer Center, discusses complementary therapy for patients with myeloproliferative neoplasms (MPNs).

Joshua Bauml, M.D., assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the potential of therapeutic vaccine in patients who have head and neck cancer.

William G. Wierda, M.D., Ph.D., medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses how to best combine and sequence therapies for patients with chronic lymphocytic leukemia (CLL).

Genetic testing – particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer.

Now that we're in an era of personalized medicine, patients should not look at statistics and immediately think that they will determine their fate, says Tom Stockwell, patient navigator at the Fibrolamellar Cancer Foundation.

Radhakrishnan Ramchandren, M.D., from the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, discusses the role of clinical trials in developing news drugs and standards of care for patients with lymphoma.

Marina Chiara Garassino, M.D., talks about how immunotherapy agents have vastly improved the treatment field of patients with non-small cell lung cancer.

Carole Brennan Miller, M.D., head of the Cancer Institute at Saint Agnes Hospital, explains what makes people with myeloproliferative neoplasms (MPNs) unique, and why she finds it interesting to work with them.

A myeloproliferative neoplasm survivor and advocate offers advice on how loved ones can support a patient with cancer.

Cristiana Sessa, M.D., of the Oncology Institute of Southern Switzerland, discusses the evolution of how PARP inhibitors are used to treat ovarian cancer.

Susan Leclair, Ph.D., CLS (NCA), retired lab professor at University of Massachusetts, Dartmouth, discusses how moderating an online forum for patients with myeloproliferative neoplasms (MPNs) has inspired her.

Catriona Jamieson, M.D., Ph.D., Professor of Medicine, University of California, San Diego Health Moores Cancer Center, addresses a common myth about clinical trials.

Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.

Mark Heaney, M.D., Ph.D., Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, discusses the pros and cons of patients with myeloproliferative neoplasms (MPNs) researching their diagnosis online.

Catriona Jamieson, M.D., Ph.D., Professor of Medicine, University of California, San Diego Health Moores Cancer Center, discusses what people diagnosed with myeloproliferative neoplasms (MPN) need to consider when choosing among providers and treatment options.

Gabriela Hobbs, M.D., discusses how to manage symptoms associated with a myeloproliferative neoplasm diagnosis.

Lindsey M. Lyle, M.S., offers advice to patients with newly diagnosed myeloproliferative neoplasms.

Barbara Abernathy, Ph.D., CEO of the Pediatric Oncology Support Team, explains how she is inspired by her work with children who have cancer.

Martha Raymond, founder and CEO of the Raymond Foundation, discusses how her organization helps to provide a voice for patients with gastrointestinal (GI) cancers.

Julia Nangia, M.D., assistant professor at Baylor College of Medicine, discusses the impact that chemotherapy-related hair loss can have on patients with breast cancer.

David R. Gandara, M.D., UC Davis Comprehensive Cancer Center, discusses how diagnostic and therapeutic changes are happening alongside one another in non-small cell lung cancer.

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, talks about the direction of research in the ovarian cancer field going into 2018 and beyond.